Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Thu, 10.02.2022
Valneva SE
First Berlin Equity Research hat ein Research Update zu Valneva SE (ISIN:
FR0004056851) veröffentlicht. Analyst Simon Scholes bestätigt seine
BUY-Empfehlung und senkt das Kursziel von EUR 23,40 auf EUR 22,10.
Zusammenfassung:
Valneva hat ihren Umsatz und ihre Liquiditätsposition für 2021 bekannt
gegeben und eine erste Umsatzp [ … ]
Thu, 10.02.2022
Media and Games Invest SE
First Berlin Equity Research hat ein Research Update zu Media and Games
Invest SE (ISIN: MT0000580101) veröffentlicht. Analyst Ellis Acklin
bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 8,20.
Zusammenfassung:
MGI kündigte Pläne an, ihren Hauptsitz von Malta nach Schweden zu verlegen.
Vorbehaltlich de [ … ]
Thu, 10.02.2022
Cardiol Therapeutics Inc.
Upcoming Investor Event:
Cardiol Therapeutics to present at digital International Investment Forum
(IIF)
On February 17, the IIF International Investment Forum will take place. At
this forum, Cardiol Therapeutics will also present its business model and
current business development.
Presentation slot:
Cardiol Therapeutics Inc. (ISIN: CA14161Y2 [ … ]
Thu, 10.02.2022
Defence Therapeutics Inc.
Uniquely Positioned with versatile ACCUM(TM); Enormous upside potential;
Next generation of cancer treatment
- Proprietary platform technology with proven enhanced intracellular
delivery. Promotes delivery of target product without non-specific
protein/antigen degradation or interference.
- Strong versatility of the Accum(TM) platf [ … ]
Wed, 09.02.2022
MagForce AG
In the past fiscal year 2021, MagForce AG made progress in both business
segments. Of particular note here is the approval granted by the FDA for
the start of Stage 2b for the treatment of prostate cancer patients. This
means that the pivotal study could be concluded as early as summer 2022. In
parallel, the treatment capacities for the indication [ … ]
Wed, 09.02.2022
Ikonisys SA
Important client-win in Italy
After the first sale of the new-gen microscope, the Ikoniscope20, to one of
the biggest genetic laboratories in Italy, we confirm our Buy rating for
the shares of Ikonisys and our three-stage discounted cash flow entity
model (primary valuation method) share price target of EUR 7.70.
Ikonisys announced the sale an [ … ]
Tue, 08.02.2022
Kleos Space S.A.
First Berlin Equity Research hat ein Research Update zu Kleos Space S.A.
(ISIN: AU0000015588) veröffentlicht. Analyst Kimberly Purvis bestätigt ihre
BUY-Empfehlung und senkt das Kursziel von AUD 5,00 auf AUD 2,70.
Zusammenfassung:
Kleos Space hat die Finanzzahlen für das 4. Quartal 21 und das Jahresende
vorgelegt und ein Update f& [ … ]
Wed, 02.02.2022
Saturn Oil & Gas Inc.
Oxbow facilities
We had the chance to visit the newly acquired Oxbow Asset in September
2021. The site visit included a complete tour and presentation of new
management as well as a trip to production assets, pads, facilities and an
introduction to many employees and contractual companies. The assets
visited were located in a fairly concentrated [ … ]
Wed, 02.02.2022
Cogia AG
Preliminary results significantly above forecast, price target confirmed
On January 21, 2022, Cogia AG published its preliminary figures for the
2021 financial year and the figures presented exceed the GBC analysts'
forecasts. A total output of EUR 1.7 million was achieved in the group,
which corresponds to almost a threefold increase (previous [ … ]
Mon, 31.01.2022
PAION AG
First Berlin Equity Research hat ein Research Update zu PAION AG (ISIN:
DE000A0B65S3) veröffentlicht. Analyst Simon Scholes bestätigt seine
BUY-Empfehlung und senkt das Kursziel von EUR 4,10 auf EUR 3,80.
Zusammenfassung:
Im vergangenen Jahr haben PAIONs Partner Remimazolam in den USA für die
Kurzsedierung und in Südkorea f&u [ … ]
